At the request of the FDA, the companies have submitted available data on the safety and efficacy of two 3 µg doses as part of a three-dose primary series for children aged 6 months old to 4 years old.
The acquisition marks Hikma’s expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.